ABSTRACT
High throughput molecular and functional profiling of patients is a key driver of precision medicine. DNA and RNA characterization has been enabled at unprecedented cost and scale through rapid, disruptive progress in sequencing technology, but challenges persist in data management and interpretation. We analyze the state-of-the-art of large-scale unbiased sequencing in drug discovery and development, including technology, application, ethical, regulatory, policy and commercial considerations, and discuss issues of LUS implementation in clinical and regulatory practice.
Subject(s)
Databases, Factual/trends , Drug Discovery/trends , Pharmacogenetics/trends , Databases, Factual/legislation & jurisprudence , Databases, Factual/standards , Delivery of Health Care/trends , Drug Discovery/legislation & jurisprudence , Drug Discovery/standards , Genetic Testing , High-Throughput Nucleotide Sequencing , Humans , Pharmacogenetics/legislation & jurisprudence , Pharmacogenetics/standards , Precision Medicine , United States , United States Food and Drug AdministrationABSTRACT
HIV-1 budding appears to require Vps4 and Tsg101-two proteins that have links to endosomal sorting machinery. A picture emerges wherein divergent viruses recruit endosomal proteins like Tsg101 to gain access to ubiquitin processes that play a crucial role during viral budding.
